{
    "clinical_study": {
        "@rank": "163254", 
        "acronym": "Poseidon", 
        "arm_group": [
            {
                "arm_group_label": "Pomalidomide following lenalidomide", 
                "description": "75 patients with pomalidomide directly following lenalidomide treatment"
            }, 
            {
                "arm_group_label": "Pomalidomide following other therapy", 
                "description": "75 patients with pomalidomide following any other prior therapy. This includes \tlenalidomide in earlier lines than the most recent line."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this non-interventional study is to collect data on the efficiency and safety\n      of pomalidomide in combination with dexamethasone in the routine application"
        }, 
        "brief_title": "Non-interventional Study With Pomalidomide (Imnovid\u00ae)", 
        "completion_date": {
            "#text": "January 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with relapsed or refractory multiple myeloma Patients must have received at\n             least two prior lines of treatment (induction therapy followed by stem cell\n             transplantation \u00b1 maintenance therapy is considered one prior therapy) and must have\n             progressed under the most recent therapy regimen\n\n          -  Adult male and female patients (at least 18 years with no upper age limit)\n\n          -  Written informed consent to data collection and pseudonymized data transfer\n\n          -  The conditions of the Pregnancy Prevention Programme must be fulfilled for all\n             patients unless there is reliable evidence that the patient does not have\n             childbearing potential (see summary of product characteristics Imnovid\u00ae)\n\n          -  Other criteria according to summary of product characteristics Imnovid\u00ae\n\n        Exclusion Criteria:\n\n          -  Missing patient's informed consent\n\n          -  Pregnant or breast-feeding women\n\n          -  Male patients, not capable of complying the required preventive measures (see\n             summary of product characteristics Imnovid\u00ae)\n\n          -  Other criteria according to summary of product characteristics Imnovid\u00ae"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients with relapsing or refractory multiple myeloma previously treated with at\n        least two prior lines of therapy, including bortezomib and lenalidomide who have\n        progressed under their last therapy regimen"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075996", 
            "org_study_id": "IOM-10280"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone", 
                "Lenalidomide", 
                "Thalidomide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "pomalidomide, Imnovid, dexamethasone, Poseidon, multiple myeloma, daily routine, secondary malignancies, Germany, non-interventional study, safety,", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "contact": {
                "email": "beate.teichmann@iomedico.com", 
                "last_name": "Beate Teichmann, PhD", 
                "phone": "076115242", 
                "phone_ext": "13"
            }, 
            "facility": {
                "address": {
                    "city": "Freiburg", 
                    "country": "Germany", 
                    "state": "Baden-Wuerttemberg", 
                    "zip": "79108"
                }, 
                "name": "iOMEDICO AG"
            }, 
            "investigator": {
                "last_name": "Tobias Dechow, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "2", 
        "official_title": "Non-interventional Study of Pomalidomide (Imnovid\u00ae) in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "beate.teichmann@iomedico.com", 
            "last_name": "Beate Teichmann, PhD", 
            "phone": "+4976115242", 
            "phone_ext": "13"
        }, 
        "overall_official": {
            "affiliation": "practice based oncology office Ravensburg", 
            "last_name": "Tobias Dechow, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "6 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075996"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }, 
            {
                "measure": "Time to Treatment Discontinuation (TTD)", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }, 
            {
                "measure": "Time to next treatment (TNT)", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }, 
            {
                "measure": "adverse reaction profile", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "description": "long term safety is focused on secondary malignancies", 
                "measure": "secondary malignancies", 
                "safety_issue": "Yes", 
                "time_frame": "6 years"
            }, 
            {
                "measure": "overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }, 
            {
                "measure": "relative dose intensity of pomalidomide and dexamethasone", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "assess changes in myeloma-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "To explore additional supportive therapies used on this patient population (e.g. G-CSF, antibiotics, DVT prophylaxis)", 
                "measure": "explore additional supportive therapies", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "iOMEDICO AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "iOMEDICO AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}